Global opisthorchiasis treatment market is projected to register CAGR growth in the forecast years, 2023-2027 on the account of growth factors like increasing instances of infectious diseases caused due to liver flukes. Also, increasing demand for raw seafood among the global population along with the lack of information about the parasitic infection caused by Opisthorchis Viverrini, is driving the growth of the global opisthorchiasis treatment market in the upcoming five years.

Opisthorchiasis is a parasitic infectious disease that passes from marine animals turned into raw sea food to humans. Opisthorchis Viverrini and Opisthorchis Felineus are the two species of the opisthorchis genus that are majorly responsible for the infectious disease spread among humans. Prolonged infection exposure, and chronic conditions may lead to cholangiocarcinoma which is a form of malignant cancer in the bile duct. The disease affects Asian countries like Thailand, Vietnam, Korea, and China majorly where seafood consumption is high.

Increasing Aquaculture Production Drives Market Growth

Increasing instances of seafood aquaculture and increasing demand for the same is driving the growth of the global opisthorchiasis treatment market in the next five years. Increasing production of seafood and their culture for the aquatic pets and to procure other products like pearls, seaweeds, etc. aquaculture is rapidly expanding and thus increasing the chances and risks of opisthorchiasis thereby supporting the growth of the global opisthorchiasis treatment market in the future five years.

According to the FAO report on State of World Fisheries and Aquaculture 2020, 82.1 million tonnes of aquatic animals, 32.4 million tonnes of aquatic algae and around 26,000 tonnes of ornamental seashells and pearls were produced in 2020. The production further leads to increased consumption and Opisthorchis Viverrini, that passes as embryonated eggs that pass in human feces settles on skin and flesh of the marine life and ultimately reaches inside human gastrointestinal tract and causes opisthorchiasis such that demand for the effective treatment is increasing and thus substantiate the growth of the global opisthorchiasis treatment market in the future five years.

Untreated Waste Dump In Waterbodies Support Market Growth

Although awareness about the environment depletion due to untreated waste dump in the ocean and other water bodies is created, still excessive amount of waste is directly dumped in the waterbodies, thus aiding to the increasing infections in the marine life and their consumption further infects human lives.

Opisthorchis Viverrini and Opisthorchis Felineus are found all over Asian waters, and European countries too. Opisthorchis Viverrini is found mainly in northeast Thailand, Laos, Cambodia, and central and southern Vietnam. Opisthorchis Felineus is found mainly in Italy, Germany, Belarus, Russia, Kazakhstan, and Ukraine.


Click here to download the sample

Market Segmentation

The global opisthorchiasis treatment market segmentation is based on type, diagnostic procedure, symptom, end user, regional distribution, and competitive landscape. Based on type, the market is divided between medications and surgery. Medication is further sub-segmented into antibiotics, anthelmintics, and others. Based on diagnostic procedure, the market is further differentiated into cholangiography, MRI, ultrasonography, CT scan, and others.

Symptom segment of the market is also fragmented into jaundice, diarrhea, fever, splenomegaly, weight loss, tachycardia, and others. Based on end user the market is again bifurcated into hospitals & clinics, ambulatory care centers, and others. The market analysis also studies the regional segmentation, divided among Asia-Pacific region, North American region, European region, South American region, and Middle East & African region.

Company Profile

Cipla Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., AbbVie Inc., Mankind Pharma Limited, are enlisted in a partial list of major market players of the global opisthorchiasis treatment market.

Attribute

Details

Base Year

2021

Historical Data

2017 – 2020

Estimated Year

2022

Forecast Period

2023 – 2027

Quantitative Units

Revenue in USD Million, and CAGR for 2017-2021 and 2022-2027

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments covered
  • Type
  • Diagnostic Procedure
  • Symptom
  • End User

Regional scope

North America; Europe; Asia Pacific; South America; Middle East & Africa

Country scope

United States, Mexico, Canada, China, India, Japan, South Korea, Australia, Germany, France, United Kingdom, Spain, Italy, South Africa, UAE, Saudi Arabia, Brazil, Argentina, Colombia

Key companies profiled

Cipla Inc., Johnson & Johnson, Sun Pharmaceutical Industries Ltd., Merck KGaA, Boehringer Ingelheim International GmbH, Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., AbbVie Inc., Mankind Pharma Limited

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global opisthorchiasis treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Opisthorchiasis Treatment Market, By Type:
    • Medications
      • Antibiotics
      • Anthelmintics
      • Others
    • Surgery
  • Opisthorchiasis Treatment Market, By Diagnostic Procedure:
    • Cholangiography
    • MRI
    • Ultrasonography
    • CT scan
    • Others
  • Opisthorchiasis Treatment Market, By Symptom:
    • Jaundice
    • Diarrhea
    • Fever
    • Splenomegaly
    • Weight loss
    • Tachycardia
    • Others
  • Opisthorchiasis Treatment Market, By End User:
    • Hospitals & Clinics
    • Ambulatory Care Centers
    • Others
  • Opisthorchiasis Treatment Market, By Region:
    • North America
      • United States
      • Mexico
      • Canada
    • Europe
      • France
      • Germany
      • United Kingdom
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • India
      • Japan
      • South Korea
      • Australia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
    • South America
      • Brazil
      • Argentina
      • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global opisthorchiasis treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Opisthorchiasis treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Opisthorchiasis Treatment Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Prevalence, By Geography

5.2.  Prevalence, By Gender

5.3.  Commonly Observed Symptoms

5.4.  Preferred Choice of Treatment

6.    Global Opisthorchiasis Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type (Medications v/s Surgery)

6.2.1.1.         By Medications (Antibiotics, Anthelmintics, Others)

6.2.2.     By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

6.2.3.     By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

6.2.4.     By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

6.2.5.     By Company (2021)

6.2.6.     By Region

6.3.  Product Market Map

7.    North America Opisthorchiasis Treatment Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type (Medications v/s Surgery)

7.2.1.1.         By Medications (Antibiotics, Anthelmintics, Others)

7.2.2.     By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

7.2.3.     By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

7.2.4.     By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

7.2.5.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Opisthorchiasis Treatment Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.2.             By Diagnostic Procedure

7.3.1.2.3.             By Symptom

7.3.1.2.4.             By End User

7.3.2.     Mexico Opisthorchiasis Treatment Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.2.             By Diagnostic Procedure

7.3.2.2.3.             By Symptom

7.3.2.2.4.             By End User

7.3.3.     Canada Opisthorchiasis Treatment Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.2.             By Diagnostic Procedure

7.3.3.2.3.             By Symptom

7.3.3.2.4.             By End User

8.    Europe Opisthorchiasis Treatment Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type (Medications v/s Surgery)

8.2.1.1.         By Medications (Antibiotics, Anthelmintics, Others)

8.2.2.     By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

8.2.3.     By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

8.2.4.     By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

8.2.5.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Opisthorchiasis Treatment Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.2.             By Diagnostic Procedure

8.3.1.2.3.             By Symptom

8.3.1.2.4.             By End User

8.3.2.     Germany Opisthorchiasis Treatment Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.2.             By Diagnostic Procedure

8.3.2.2.3.             By Symptom

8.3.2.2.4.             By End User

8.3.3.     United Kingdom Opisthorchiasis Treatment Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.2.             By Diagnostic Procedure

8.3.3.2.3.             By Symptom

8.3.3.2.4.             By End User

8.3.4.     Italy Opisthorchiasis Treatment Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type

8.3.4.2.2.             By Diagnostic Procedure

8.3.4.2.3.             By Symptom

8.3.4.2.4.             By End User

8.3.5.     Spain Opisthorchiasis Treatment Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type

8.3.5.2.2.             By Diagnostic Procedure

8.3.5.2.3.             By Symptom

8.3.5.2.4.             By End User

9.    Asia-Pacific Opisthorchiasis Treatment Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type (Medications v/s Surgery)

9.2.1.1.         By Medications (Antibiotics, Anthelmintics, Others)

9.2.2.     By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

9.2.3.     By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

9.2.4.     By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

9.2.5.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Opisthorchiasis Treatment Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Diagnostic Procedure

9.3.1.2.3.             By Symptom

9.3.1.2.4.             By End User

9.3.2.     India Opisthorchiasis Treatment Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Diagnostic Procedure

9.3.2.2.3.             By Symptom

9.3.2.2.4.             By End User

9.3.3.     South Korea Opisthorchiasis Treatment Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Diagnostic Procedure

9.3.3.2.3.             By Symptom

9.3.3.2.4.             By End User

9.3.4.     Japan Opisthorchiasis Treatment Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Type

9.3.4.2.2.             By Diagnostic Procedure

9.3.4.2.3.             By Symptom

9.3.4.2.4.             By End User

9.3.5.     Australia Opisthorchiasis Treatment Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Type

9.3.5.2.2.             By Diagnostic Procedure

9.3.5.2.3.             By Symptom

9.3.5.2.4.             By End User

10.  South America Opisthorchiasis Treatment Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type (Medications v/s Surgery)

10.2.1.1.      By Medications (Antibiotics, Anthelmintics, Others)

10.2.2.  By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

10.2.3.  By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

10.2.4.  By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

10.2.5.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Opisthorchiasis Treatment Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By Diagnostic Procedure

10.3.1.2.3.           By Symptom

10.3.1.2.4.           By End User

10.3.2.  Argentina Opisthorchiasis Treatment Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By Diagnostic Procedure

10.3.2.2.3.           By Symptom

10.3.2.2.4.           By End User

10.3.3.  Colombia Opisthorchiasis Treatment Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By Diagnostic Procedure

10.3.3.2.3.           By Symptom

10.3.3.2.4.           By End User

11.  Middle East and Africa Opisthorchiasis Treatment Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type (Medications v/s Surgery)

11.2.1.1.      By Medications (Antibiotics, Anthelmintics, Others)

11.2.2.  By Diagnostic Procedure (Cholangiography, MRI, Ultrasonography, CT scan, Others)

11.2.3.  By Symptom (Jaundice, Diarrhea, Fever, Splenomegaly, Weight loss, Tachycardia, Others)

11.2.4.  By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)

11.2.5.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Opisthorchiasis Treatment Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type

11.3.1.2.2.           By Diagnostic Procedure

11.3.1.2.3.           By Symptom

11.3.1.2.4.           By End User

11.3.2.  Saudi Arabia Opisthorchiasis Treatment Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type

11.3.2.2.2.           By Diagnostic Procedure

11.3.2.2.3.           By Symptom

11.3.2.2.4.           By End User

11.3.3.  UAE Opisthorchiasis Treatment Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Type

11.3.3.2.2.           By Diagnostic Procedure

11.3.3.2.3.           By Symptom

11.3.3.2.4.           By End User

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1.              Cipla Inc.

14.2.              Johnson & Johnson

14.3.              Sun Pharmaceutical Industries Ltd.

14.4.              Merck KGaA

14.5.              Boehringer Ingelheim International GmbH

14.6.              Pfizer Inc.

14.7.              GlaxoSmithKline plc

14.8.              F. Hoffmann-La Roche Ltd

14.9.              AbbVie Inc

14.10.            Mankind Pharma Limited

15.  Strategic Recommendations

16.  About Us & Disclaimer

In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com